Abstract
Squalene epoxidase inhibitors represent an attractive target for the control of sterol biosynthesis. Success in the search for fungal squalene epoxidase inhibitors has led to commercial availability of drugs from this class (e.g., terbinafine from Sandoz). The discovery of NB-598, a potent and selective mammalian squalene epoxidase inhibitor able to decrease serum low density lipoprotein-cholesterol levels in dogs, with a similar potency to simvastatin, has stimulated increased efforts towards the identification of new mammalian squalene epoxidase inhibitors. Such compounds represent an attractive alternative to 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors as new therapeutic tools in the control of plasma low density lipoprotein-cholesterol levels, a major risk factor in coronary artery diseases. This article describes the recent development of this class of compounds, reviewing both the primary and patent literature.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
